Mutations in the isocitrate dehydrogenase gene (IDH, including IDH1 and IDH2) were reported to characterize the majority of lower‐grade gliomas and to be associated with better overall survival (OS) (Parsons et al., 2008). This evidence concerns the gene IDH1 and central nervous system cancer.